Current Problems in the Management of Chronic Myeloid Leukemia in Turkey

DEMİRKAN F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.21, sa.2, ss.24-28, 2011 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 21 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.4999/uhod.11015
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.24-28
  • Anahtar Kelimeler: Chronic myeloid leukemia, Tyrosine kinase inhibitors, BCR/ABL, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, CHRONIC-PHASE, MOLECULAR RESPONSES, FOLLOW-UP, INTERFERON, DASATINIB, THERAPY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Although a large scale survey investigating the practice patterns of physicians for Chronic Myeloid Leukemia (CML) throughout Turkey is absent, there is an increasing enthusiasm on this subject after several years of experience with Tyrosine Kinase Inhibitors (TKI) therapy. Considering the problems in the management of CML patients, we can focus on deficiencies in the laboratory tests for diagnosis and monitoring, management of suboptimal response with imatinib therapy and conducting visit frequency of patients.